Core Insights - The State Grid has announced a "14th Five-Year" plan with an expected fixed asset investment of 4 trillion yuan, focusing on the construction of a new power system centered around ultra-high voltage, smart distribution networks, and digitalization [1] Group 1: Company Positioning - Huashengchang (002980) is positioning itself as a specialized provider of measurement and testing solutions, targeting the new power system's detection and operation and maintenance (O&M) sectors [1] - The company has a wide product line covering various professional fields such as electrical power, infrared thermal imaging, and environmental monitoring, designed to meet diverse measurement and O&M needs across power, transportation, meteorology, and electromechanical maintenance [1] Group 2: Product Offerings - The DT-1500PV multifunctional photovoltaic testing instrument integrates photovoltaic I-V curve measurement and safety testing, enhancing the efficiency and safety of photovoltaic power station operations [2] - The company offers a comprehensive power quality detection solution that includes the DT-7760 high-end power quality analyzer and AI-7760 intelligent power quality analyzer, providing a full-link approach to monitoring, analysis, governance, and verification [3] - The new generation AI arc detection series products are designed for safer and smarter applications in new energy power stations and energy storage systems, capable of precise analysis and rapid detection of arc signals, ensuring reliable operation of new energy systems [3]

Core Viewpoint - The company aims to redefine the value of measurement instruments through AI technology, emphasizing the importance of precise measurement in industrial and social operations [1] Group 1: Product Launch - Four AI-powered medical devices were launched, including a smart blood pressure monitor with an AI voice assistant, addressing common issues faced by elderly users [2] - The product lineup also includes a dual-level ventilator, a portable six-lead ECG device, and a combined blood pressure and ECG monitor, all designed to meet family health needs [2] Group 2: Technology and Innovation - The new products are positioned as health management tools rather than mere measurement devices, achieving medical-grade data accuracy through over 30 years of sensor technology and data analysis [3] - The DeepSense model, a generative AI service, has been officially registered and is designed to provide intelligent support and integrated solutions for measurement and detection industries [3][4] Group 3: Future Development - The company plans to leverage AI to reconstruct its entire product line, aiming to drive digital transformation in the measurement instrument industry [6] - A new subsidiary has been established to focus on AI upgrades, with plans to develop AI glasses tailored to user needs, enhancing measurement capabilities in various applications [6]

Financial Performance - In Q1 2025, the company achieved revenue of 40,369.1 million RMB, a year-on-year increase of 26.47% [2] - The net profit attributable to shareholders was 29,159.5 million RMB, reflecting a growth of 6.25% compared to the previous year [2] - Excluding the impact of share-based payments, the net profit attributable to shareholders was 37,633.9 million RMB, with a growth rate of 37.13% [2][3] Future Performance Goals - The company has set performance targets for 2024 to 2026, aiming for net profit or revenue growth rates of 25%, 50%, and 75% respectively compared to 2023 [3] - The management maintains a positive outlook for the 2025 performance assessment [3] Dividend Policy - The company is committed to a sustainable and stable profit distribution policy, adhering to legal requirements and considering shareholder interests [3] - The proposed dividend for 2024 is 7.3 RMB per 10 shares (tax included), with a capital reserve conversion of 4 additional shares for every 10 shares held [4] Growth Drivers - The company’s revenue for 2024 was 80,749.78 million RMB, a year-on-year increase of 20.55%, with a net profit of 13,842.49 million RMB, reflecting a growth of 29.21% [5] - Key growth factors include product structure optimization, increased revenue from proprietary brands, and a focus on large customer development strategies [6] Market Strategy - The company has diversified its global marketing strategy to mitigate risks associated with the U.S. market, maintaining stable operations and production capacity in Vietnam [8] - The medical diagnostics and life sciences analysis instruments segment is a strategic focus, with plans to integrate AI technology into existing products [9][11] R&D Investment - R&D investment has increased from 47.17 million RMB in 2020 to 90.45 million RMB in 2024, with a compound annual growth rate of 19.4% [13] - The focus areas for R&D include integrating large model technology into smart instruments and expanding the product matrix to align with international standards [13]